Seeking Alpha

Sequenom (SQNM -2.3%) goes into the close a bit stronger than it started out the day, recovering...

Sequenom (SQNM -2.3%) goes into the close a bit stronger than it started out the day, recovering some of its earlier 6% dip on some upbeat preliminary FY12 guidance posted over the weekend. The company said that it is expecting revenues of $89M, equating to a Y/Y growth rate of 59%, but the results were largely overshadowed by Illumina's (ILMN -7.3%) acquisition of Verinata, whose competing verifi test - which analyzes fetal DNA naturally found in a pregnant women's blood to look for missing or extra copies of chromosomes - carry's less risk than Sequenom’s SEQureDx technology.

Check out Seeking Alpha’s new Earnings Center »

Comments (2)
  • Director one
    , contributor
    Comments (61) | Send Message
     
    Get the story right.......There is no risk with SQNM test plus it is more accurate than verinata
    7 Jan 2013, 04:11 PM Reply Like
  • ceekay
    , contributor
    Comments (10) | Send Message
     
    Less risk??????than SQNM's test...Please do your research...Thanks
    7 Jan 2013, 04:33 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs